
Biotech · San Francisco, California
Rezo Therapeutics
Rezo is a biopharma company building a disease-agnostic, fully integrated network biology platform to dramatically increase drug development success, led by UCSF-origin founders with a proven track record of FDA-approved drugs.
Work at Rezo Therapeutics?
- Location
- San Francisco
- On-site · 4 roles
- Team size
- 11-50
- Total raised
- $78M
- Series A · last round Nov '22
- Salary range
- $160–370k
- 3 of 4 roles
Open positions · 4
About Rezo Therapeutics
Rezo is a biopharma company. Rezo's mission is to dramatically increase the success rate of drug development by building a disease-agnostic, fully-integrated, network biology platform that will redefine our understanding of human disease and ability to treat it. The company describes itself as a different kind of biopharma company. Its founders and board, including Nevan Krogan, Kevan Shokat, Sourav Bandyopadhyay, Natalia Jura, George Scangos, and Norbert Bischofberger, are from the University of California, San Francisco, and bring a strong track record of discoveries and scientific breakthroughs, leading to successful companies and many FDA-approved drugs.
Funding
$78Mtotal raised
- Nov 2022 · Series A$78M
Company at a glance
The team at Rezo Therapeutics
11-50 peopleSee everyone on LinkedIn
Location
Life at Rezo Therapeutics
Frequently asked questions
Of 4 open roles, Rezo Therapeutics has 4 on-site positions.
Rezo Therapeutics is based in San Francisco, California.
Ask your AI about Rezo Therapeutics
Connect Clera once, then ask what they're hiring for.
Ask about this company
What is Rezo Therapeutics hiring for on Clera (https://www.getclera.com/companies/rezo-therapeutics)? Tell me which of those roles fit my profile, and tell Clera I'm interested in the best one.
Not connected yet? Takes a minute
https://mcp.getclera.comSign in with your Clera account. MCP docs
Companies similar to Rezo Therapeutics
We're building the first AI-native go-to-market agency in the DACH region. Since 2024, we've grown to over €5M ARR and a team of 30+, working with more than 200 leading B2B tech companies.
Augustus is building the global dollar bank. Moving dollars across borders still runs on correspondent banking, a chain of intermediaries that is slow, opaque, and expensive. Augustus replaces it with programmable USD and EUR accounts, direct clearing and settlement, and an AI-native core banking platform built from scratch. The moat is the license. Augustus holds OCC conditional approval for a US national bank charter, which is rare and very hard to replicate, and euro clearing is live today for customers including Kraken. $180M Series B at a $1B valuation, led by Tiger Global with QED, plus operators from Nubank, Ramp, Circle, Revolut, and Coinbase. Fewer than 50 people, in NYC and Berlin.
Aurelius Systems is the autonomous laser company. It combines AI, robotics and directed energy to defeat drones at scale. Its flagship system, Archimedes, detects, tracks and neutralizes Group 1-2 UAS autonomously: a robotic, low-SWaP, ground- and power-agnostic laser weapon deployable on land, sea and air platforms. The full stack is built in-house, from perception, autonomy, controls, optics, power and embedded systems to fire control, C2 and AI software. Aurelius builds its own software stack. The company is also standing up U.S. production of high-power fiber lasers, the most cost- and supply-constrained component in any directed-energy system.
